I am delighted to announce four new leaders at UC San Diego Altman Clinical and Translational Research Institute (ACTRI). They offer special expertise and fresh insight in the areas of biomedical informatics, computational biology, clinical trials, and mentoring of the next generation of translational scientists. By continuously adding and refreshing the outstanding talent that works at the ACTRI, we aim to facilitate research, support our less experienced investigators, and provide new tools at UC San Diego for our investigators.
ACTRI welcomes the following additions to our team:
Kathleen Fisch, PhD, is the new executive director of the Center for Computational Biology and Bioinformatics group. Dr. Fisch, an accomplished researcher in computational genomics and systems biology approaches, leads a team of computational biologists and bioinformatics engineers and facilitates collaboration with faculty and researchers on human disease research-related projects requiring computational genomics, network analysis methods and systems biology approaches.
Kathryn A. Gold, MD, is the new associate director of ACTRI Clinical Research Services. Dr. Gold is an oncologist whose clinical and translational research interests include lung and head and neck cancer, with a focus on target therapies and immunotherapies. Serving in this newly created position at ACTRI, she assists Mark S. Wallace, MD, director of the ACTRI Division of Clinical Research Services, in the day-to-day functions of the division. The division manages a dedicated research clinic that includes 18,000 square feet of state-of-the-art facilities for all phases of clinical research and supports more than 250 clinical protocols each year.
Michael Hogarth, MD,
is the new director of the ACTRI Biomedical Informatics (BMI) unit. Dr. Hogarth, who will also serve as the Clinical Research Information Officer (CRIO) at UC San Diego Health, is a leading informatician whose research relates to health information technology, with particular interests in clinical research, biomedical natural language processing, and databases. He is responsible for leading efforts to align and integrate resources in Information Services with clinical research informatics, including ACTRI services. He also develops and optimizes strategies to use our current technology and systems to support the integration of research with patient care, including the use of the electronic health record (EHR) for clinical trial recruitment and EHR data for observational research.
Adriana Tremoulet, MD, MAS, is the new co-director of the KL2 program in the ACTRI Education, Training and Career Development unit. Dr. Tremoulet, a physician-researcher and an expert in Kawasaki’s Disease, will support mentorship of KL2 scholars and help oversee programs for junior faculty involved in clinical and translational research in the ACTRI. She co-directs the KL2 Program, a key component of the ACTRI Education unit, with ACTRI Education Director Colin Depp, PhD and Joel Dimsdale, MD.
The addition of these leaders are important changes in our organization as we move forward in our mission to advance translational medicine. They offer new possibilities for how we can improve and expand, and we are excited about their contributions. We are also grateful to the leaders who have served us during our formative years. We thank Dr. Dimsdale for his exceptional leadership in the development of the KL2 Program at ACTRI and Dr. Lucila Ohno-Machado for her outstanding leadership in establishing the BMI unit at ACTRI.
Please join me in welcoming the latest additions to our leadership team.
Gary S. Firestein, MD, Director of ACTRI
Distinguished Professor of Medicine
Dean and Associate Vice Chancellor of Translational Medicine
Phone: (858) 822-3824
Read the announcement about Dr. Gold
Read the announcement about Dr. Hogarth
Read the announcement about Dr. Tremoulet